PeriRx LLC, a premier developer of breakthrough, noninvasive, oral diagnostic technology, recently announced that it will be introducing the world’s most clinically advanced and scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma detection in the late spring.
MORE ON ORAL CANCER...
The Big "C": What's the latest?
April is Oral Cancer Awareness Month
The details of oral cancer screening
Before you look at the teeth, look at this: our responsibility to detect and treat oral cancer
Head, neck, and oral cancer: A general reference for treatment
According to PeriRx LLC’s CEO Stephen M. Swanick, “This is a simple-to-use, painless, and noninvasive test designed for front line health-care practitioners that enables them to detect disease earlier, enhance patient wellness, and reduce the overall cost of health care.”
The salivary test is based on a strong scientific foundation of NIH-funded research with initial discovery and pre-validation work by Dr. David Wong of the University of California at Los Angeles. The test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.
These discriminatory salivary biomarkers have been clinically validated in multiple large trials including studies in collaboration with the National Cancer Institute and with premiere US academic medical centers such as the University of Michigan, Michigan State University, and the Providence Health System in Detroit.
For more information, visit www.PeriRx.com. To become an early adopter of the salivary test, or to become an investor in PeriRx LLC, contact Stephen M. Swanick at (610) 449-9625 or [email protected].
About PeriRx LLC
Based in Havertown, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, noninvasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.
The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.
PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through FDA approval, and into commercialization.
